Photo from academic.microsoft.com
Inhibitors of sodium–glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase 4 (DPP4) are widely used in patients with type 2 diabetes to improve glycaemic control and reduce cardiovascular risks. Two recent… Click to show full abstract
Inhibitors of sodium–glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase 4 (DPP4) are widely used in patients with type 2 diabetes to improve glycaemic control and reduce cardiovascular risks. Two recent clinical trials, CREDENCE and DELIGHT, demonstrate that these drugs can also slow down the progression of kidney disease in these patients.
Keywords:
nephrology;
delight deliver;
credence;
credence delight;
renal benefits;
deliver renal
Journal Title: Nature Reviews Nephrology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Nephrology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!